Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (2): 260-264    DOI: 10.31083/j.ejgo.2020.02.4925
Original Research Previous articles | Next articles
Diabetes mellitus and epithelial ovarian cancer in Chinese women: a retrospective cohort study
Can Fang1, †, Yan Zhao2, †, Kezhen Li1, Danhui Weng1, Peng Wu1, Gang Chen1, Ding Ma1, Juncheng Wei1, *()
1 Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430079, China
2 Key Laboratory for Oral Biomedical Engineering Ministry of Education, School & hospital of Stomatology, Wuhan University, Wuhan 430079, China
Download:  PDF(749KB)  ( 271 ) Full text   ( 5 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: To determine whether diabetes mellitus (DM) effects progression-free survival (PFS) and overall survival (OS) in women with epithelial ovarian cancer (EOC). Materials and Methods: Tongji Hospital (Wuhan, China) patients presenting with EOC between 2004 and 2012 were included in a retrospective cohort study. Patients were monitored for PFS and OS through October 2014. Kaplan-Meier and log rank statistical methods were used to compare PFS and OS between diabetes mellitus patients and non-diabetic (ND) patients. Results: A total of 257 patients were included in the study and 64 (24.9%) were diagnosed with diabetes mellitus. Non-diabetic and diabetic mellitus patients were evenly distributed in age, malignant family history, tumor stage, pathology grade, body mass index (BMI), and protein levels of CA125. These results demonstrated that the DM group had worse PFS (31.0 vs. 44.0 months, p = 0.008) and OS (34.0 vs. 55.0 months, p = 0.002) when compared to the ND group. Conclusion: EOC patients with diabetes mellitus have reduced PFS and OS than patients without diabetes.
Key words:  Diabetes mellitus      Epithelial ovarian cancer      Progression-free survival      Overall survival     
Published:  15 April 2020     
Fund: 
81772775/National Science Foundation of China
81400544/National Science Foundation of China
*Corresponding Author(s):  JUNCHENG WEI     E-mail:  wjcwjc999@126.com
About author:  Contributed equally

Cite this article: 

Can Fang, Yan Zhao, Kezhen Li, Danhui Weng, Peng Wu, Gang Chen, Ding Ma, Juncheng Wei. Diabetes mellitus and epithelial ovarian cancer in Chinese women: a retrospective cohort study. European Journal of Gynaecological Oncology, 2020, 41(2): 260-264.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.02.4925     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I2/260

[1] Yudi Mulyana Hidayat, Gatot Nyarumenteng Adhipurnawan Winarno, Maringan Diapari Lumban Tobing, Arieff Kustiandi, Kemala Isnainiasih Mantilidewi, Sofie Rifayani Krisnadi. The Role of Akt2 and CA-125 Serum Levels as Predictors for Successful Cytoreduction in Epithelial Ovarian Cancer Surgery[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 739-744.
[2] Lingyun Zhai, Lixin Zeng, Hongru Jiang, Wei Li. Effects of a cyclooxygenase-1-selective inhibitor in combination with taxol or cisplatin on cyclin D1, apoptosis, and vascular endothelial growth factor in a xenograft model of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 779-784.
[3] Gen-Hai Zhu, Kang Wang, Lan Hong, Xin-Hui Fu, Fu-Jin Liu, Hai-Yan Huang. Safety and efficacy of fertility-sparing surgery for an orthotopic xenograft model of epithelial ovarian cancer in nude mice[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 609-616.
[4] Emine Karabuk, Burak Karadag, Ceyda Karadag, M. Faruk Kose, M. Murat Naki, E. Nilufer Guler. The outcomes of fertility sparing surgery in epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 391-395.
[5] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
[6] X.Z. Cheng, Z. Zhou, M.Y. Yang, Y.L. Cai, F. Deng, X.X. Chen. Prognostic factors for types I and II epithelial ovarian cancer in the elderly[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 7-15.
[7] G. Scandurra, S. Gieri, F. Marletta, B. Pecorino, S. Nicolini, G. L. Banna, G. Scibilia, P. Scollo. Safety and efficacy of new techniques of radiotherapy in oligometastatic recurrent ovarian cancer patients with BRCA1/2 mutation[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 739-743.
[8] D.G. Attiah, I. Helenowski, T. Refaat, J.B. Strauss, S. Shahabi, J. Lurain, M. Pineda, W. Nieves-Neira, D. Matei, E.D. Donnelly. Significance of number of positive lymph nodes and size as prognostic factors of recurrence and overall survival in cervical cancer patients[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 609-613.
[9] V. Pažin, A. Dobrosavljevic, L. Nejkovic. Primary fallopian tube carcinoma – case report[J]. European Journal of Gynaecological Oncology, 2019, 40(1): 163-165.
[10] Chen Mi, Cancan Zhang, Qi Zhang, Aiyun Xing. Increased expression of lncRNA HULC in human epithelial ovarian cancer and its biological functions[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 992-996.
[11] Jing Zhao, Xue Dong, Qing-cui Liu, Qun Lu. Expression of plasma miR-106a in epithelial ovarian cancer and its diagnostic and prognostic significance[J]. European Journal of Gynaecological Oncology, 2018, 39(5): 769-772.
[12] Li-Yuan Guo, San-Yuan Zhang, Chen Chen, Hao-Xia Zeng, Feng-Yan Li, Qiu-Xiang Xu. Lentinan combined with cisplatin and paclitaxel in the treatment of patients with ovarian cancer with ascites[J]. European Journal of Gynaecological Oncology, 2018, 39(4): 615-620.
[13] K. Yao, C. Bian, L. Li, Y. Wu, X. Zhao. The clinical response of advanced epithelial ovarian cancer patients to neoadjuvant chemotherapy in China[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 377-380.
[14] Jun Dai, Peishu Liu, Yangyun Liu, Wei Cai. An experimental study of cyclinD1 expression in human epithelial ovarian cancer cells[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 247-252.
[15] B.D. de-la-Noval, M.D. Diestro Tejeda, L. Yébenes, I. Zapardiel, A. Hernández Gutiérrez, J. De-Santiago García. Recurrent endometriosis following tibolone hormone replacement therapy after mucinous ovarian carcinoma[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 310-313.
No Suggested Reading articles found!